Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...

Senti Biosciences, Inc. (NASDAQ:SNTI) has rebounded strongly over the last week, with the share price soaring 68%. But that's not enough to compensate for the decline over the last twelve months.

And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its ...

Following completion of enrolment, Senti Biosciences plans FDA discussions in 2026 on pivotal registration and new AML ...

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...

Curt Herberts is signing on at synthetic biology startup Senti Biosciences as its new chief financial officer and chief business officer. First up on the docket? Figuring out the company's partnering ...

Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference, and ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and ...

Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene ...